Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 5/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 4/20 | 1.00 |
| ▸ | IDH1 | O75874 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Physalin B SCHEMBL30775538 | 1.00 | GLI1 (1.00) | GLI1NFKBIAIDH1ARBRD4 | |
| Physalin B SCHEMBL15853699 | 1.00 | GLI1 (1.00) | GLI1NFKBIAIDH1ARBRD4 | |
| Physalin B SCHEMBL28386436 | 1.00 | GLI1 (1.00) | GLI1NFKBIAIDH1ARBRD4 | |
| Physalin B SCHEMBL15856980 | 1.00 | GLI1 (1.00) | GLI1NFKBIAIDH1ARBRD4 | |
| Physalin B SCHEMBL15853692 | 1.00 | GLI1 (1.00) | GLI1NFKBIAIDH1ARBRD4 | |
| SCHEMBL31301129 | 0.88 | GLI1 (0.79) | GLI1NFKBIAIDH1 | |
| SCHEMBL15856986 | 0.81 | GLI1 (0.70) | GLI1NFKBIAIDH1 | |
| Physalin G SCHEMBL30284476 | 0.81 | GLI1 (0.68) | GLI1NFKBIAIDH1 | |
| Physalin F SCHEMBL29511415 | 0.81 | GLI1 (1.00) | GLI1NFKBIAIDH1BRD4BRD3 | |
| Physalin D SCHEMBL15853697 | 0.79 | GLI1 (0.84) | GLI1NFKBIAIDH1BRD4BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117357418-A | Use of natural products in soothing anti-sensitization cosmetics and anti-sensitization drugs | 上海致臻志臣科技有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-115869362-A | Extraction process of calyx seu fructus physalis total flavonoids and total physalins | 山西农业大学 | 2023-03-31 | — | — | CN | claimed |
| US-20220125834-A1 | LOCALIZED DELIVERY OF THERAPEUTIC AGENTS | Nostopharma, LLC | 2022-04-28 | — | — | US | claimed |
| CN-111000852-B | Application of withanolide extract in physalis angulata in preparation of drugs for preventing or treating non-alcoholic fatty liver diseases | 中国药科大学 | 2022-03-11 | — | — | CN | claimed |
| CN-111035645-B | Application of Physalin B in preparation of medicine or health product for preventing and treating non-alcoholic fatty liver disease | 中国药科大学 | 2022-03-11 | — | — | CN | claimed |
| EP-3937658-A1 | LOCALIZED DELIVERY OF THERAPEUTIC AGENTS | Nostopharma, LLC (US) | 2022-01-19 | — | — | EP | claimed |
| CN-108392484-B | Application of steroid compound in preparation of medicine for preventing or treating gastric ulcer and complications thereof | 贵州省食品药品检验所 | 2021-04-13 | — | — | CN | claimed |
| CN-112618539-A | Application of physalin B in preparation of medicine for treating acute lung injury | 广东药科大学 | 2021-04-09 | — | — | CN | claimed |
| WO-2020185784-A1 | LOCALIZED DELIVERY OF THERAPEUTIC AGENTS | Nostopharma, LLC (US) | 2020-09-17 | — | — | WO | claimed |
| EP-3681481-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HETEROTOPIC OSSIFICATION AND PATHOLOGIC CALCIFICATION | Nostopharma, LLC (US) | 2020-07-22 | — | — | EP | claimed |
| US-20090252672-A1 | NASAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS | UNIVERSITY OF MARYLAND, BALTIMORE | 2009-10-08 | — | — | US | claimed |
| CN-101422467-A | Immunosuppressant containing Withanolide type compound | UNIV EAST CHINA SCIENCE & TECH (CN) | 2009-05-06 | — | — | CN | claimed |
| EP-1993356-A2 | ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS | Alba Therapeutics Corp. (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007134241-A2 | NASAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS | UNIVERSITY OF MARYLAND BALTIMORE (US) | 2007-11-22 | — | — | WO | claimed |
| WO-2007095091-A2 | ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS | ALBA THERAPEUTICS CORPORATION (US) | 2007-08-23 | — | — | WO | claimed |
| US-20070196272-A1 | ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2007-08-23 | — | — | US | claimed |
| US-6998394-B2 | Process for isolating physalins from plants and pharmaceutical compositions containing physalins | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2006-02-14 | — | — | US | claimed |
| US-20050101519-A1 | PROCESS FOR ISOLATING PHYSALINS FROM PLANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING PHYSALINS | FUNDACAO OSWALDO CRUZ - FIOCRUZ | 2005-05-12 | — | — | US | claimed |
| US-20020103386-A1 | PROCESS FOR ISOLATING PHYSALINS FROM PLANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING PHYSALINS | FUNDACAO OSWALDO CRUZ-FIOCRUZ (BR) | 2002-08-01 | — | — | US | claimed |
| EP-1145709-A1 | Use of natural products to prepare cosmetic compositions | LABORATOIRES SEROBIOLOGIQUES (FR) | 2001-10-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103386-A1 | PROCESS FOR ISOLATING PHYSALINS FROM PLANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING PHYSALINS | AP3B1, ERG28, ENPP2 | GLI1 4306/4885NFKBIA 1479/4885IDH1 4749/4885 |
| US-20050101519-A1 | PROCESS FOR ISOLATING PHYSALINS FROM PLANTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING PHYSALINS | AP3B1, ERG28, ENPP2 | GLI1 4306/4885NFKBIA 1479/4885IDH1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.